source
- BeOne culls five cancer programs and an autoimmune Phase 2BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…Endpoints · 3mo ago↗ source
- Lonza looks to ride ADC wave with upcoming factory, workforce expansionBASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount. T…Endpoints · 3mo ago↗ source
- Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipelineCentered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.